Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study
Scandinavian Journal of Surgery · 2024-06 · 113 (2) · 140-149
DOI: 10.1177/14574969231200653 ↗At a glance
Kohortenstudie in Scandinavian Journal of Surgery, published online on 2023-10-12. Written by Antti Yrjönen and 3 co-authors. Institution: Jorvi Hospital, Ambulatory Surgery Unit, Karvasmäentie 8, Espoo 02740 Finland. Major MEDLINE topics: Pseudomyxoma Peritonei, Cytoreduction Surgical Procedures, Peritoneal Neoplasms, Hyperthermic Intraperitoneal Chemotherapy. Cited 1 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background and Aims: Pseudomyxoma peritonei (PMP) is a rare disease characterized by progressive build-up of mucinous deposits inside the abdominal cavity. The aim of this study was to investigate the effect of disease recurrence on overall survival in patients with PMP after cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
Methods
One-hundred thirty-two consecutive PMP patients treated with CRS + HIPEC at Helsinki University Hospital between 2008 and 2017 were included. The impact of clinicopathological and treatment-related characteristics on recurrence and overall survival was evaluated.
Results
The median follow-up time in the study was 5.04 (range = 0.05–11.60) years. In 121 (91.7%) patients, the disease was classified as low grade and 11 (8.3%) had high-grade disease. In the low-grade group, 26 (21.5%) patients developed a recurrence during follow-up compared to 6 (54.5%) patients in the high-grade group. In the low-grade group, cumulative survival was 98.2%, 91.4%, and 91.4% at 3, 6, and 8 years, respectively. In the high-grade group, cumulative survival was 90.0% and 78.8% at 3 and 6 years, respectively. In patients with recurrent disease, the cumulative survival was 100%, 84.6%, and 84.6% at 3, 6, and 8 years in the low-grade category and 80.0% and 60.0% at 3 and 6 years in the high-grade category, respectively. In the low-grade group, a statistically significant correlation with recurrence but not with overall survival was identified with peritoneal cancer index (PCI), carcinoembryonic antigen (CEA), and the number of affected regions.
Conclusion
The recurrence of low-grade PMP does not significantly affect overall survival of patients. Disease extent may not be a prognostic indicator after curative CRS and HIPEC in low-grade PMP.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Jorvi Hospital, Ambulatory Surgery Unit, Karvasmäentie 8, Espoo 02740 Finland.
- Abdominal Center, Department of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
ORCID profiles: Antti Yrjönen, Carola Haapamäki
Cite
APA
Yrjönen, A., Koskenvuo, L., Haapamäki, C., & Lepistö, A. (2024). Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study. Scandinavian Journal of Surgery, 113(2), 140-149. https://doi.org/10.1177/14574969231200653
Vancouver
Yrjönen A, Koskenvuo L, Haapamäki C, Lepistö A. Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study. Scandinavian Journal of Surgery. 2024;113(2):140-149. doi:10.1177/14574969231200653
BibTeX
@article{Yrjnen2024,
author = {Yrjönen, Antti and Koskenvuo, Laura and Haapamäki, Carola and Lepistö, Anna},
title = {Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study},
journal = {Scandinavian Journal of Surgery},
year = {2024},
volume = {113},
number = {2},
pages = {140--149},
doi = {10.1177/14574969231200653}
}
EUVIMED